At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 384 enrolled
Drug / intervention
SEL +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects With Moderate to Advanced Diabetic Kidney Disease
In Brief
A Phase 2 clinical trial evaluating SEL and Placebo for Diabetic Kidney Disease. Completed, enrolled 384 participants across 111 sites in 5 countries.
Detailed Summary
The primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function in participants with moderate to advanced diabetic kidney disease (DKD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Kidney Disease
CountriesAustralia, Canada, Japan, New Zealand, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartJul 2019
Primary CompletionSep 2021
TodayJul 2026
First PostedJul 19, 2019
Enrollment StartJul 24, 2019
Primary CompletionSep 3, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 7.0 years ago
Interventions
SELdrug
Tablet administered orally once daily
Placebodrug
Tablet administered orally once daily